ORPATHYS savolitinib Updated Aug 2
Watch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
- Third China approval (July 2026) for MET-amplified gastric cancer, a first-in-class claim in that setting, supported by 32.3% ORR / 4.0-month median PFS in a pivotal Phase 2 (per HUTCHMED 6-K filed 2026-07-02)
- Commercial traction: H1 2026 Oncology/Immunology marketed-product revenue up 23% to $121.4M, and ORPATHYS is already NRDL-reimbursed in China (since March 2023) for lung cancer, per H1 2026 6-K (filed 2026-07-30)
- SAFFRON global Phase 3 + SANOVO China Phase 3 topline readouts guided to H2 2026, positive results could support US/EU filings via partner AstraZeneca
- Gastric approval is CONDITIONAL, post-marketing confirmatory data are required; failure could restrict the label
- MET-amplified gastric cancer is a small niche (~18,000 patients/yr in China, ~4-6% of gastric cases) limiting the new indication's revenue ceiling
- SAFFRON/SANOVO Phase 3 readouts in H2 2026 are binary, a miss or delay stalls the ex-China expansion thesis; HUTCHMED's own risk section flags trials 'may miss endpoints'